News & Highlights

  • June 2020
  • Covid-19 Business Impact Center

Re-Starting Under Uncertainty: Managerial Experiences from Around the World

Professor Raffaella Sadun and the HBS Global Research Centers travelled virtually around the globe and talked with over 50 resilient businesses across a variety of countries and sectors. In her report, “Re-starting under uncertainty”, Professor Sadun explains, “as economies reopen after forced shutdowns caused by COVID-19, managers around the world are faced with a dual challenge: keeping the workforce safe while at the same time preserving business viability in an evolving and volatile market. How should businesses start to design their ‘new normal’ at this time of heightened uncertainty? While we are still far from knowing what constitutes a ‘best practice’, there is already a great deal of experimentation emerging all over the world.”

  • April 2020
  • Managing the Future of Work

Managing the Future of Work Podcast: Nick Dalton, Unilever

In this podcast, Professor Bill Kerr talks to Nick Dalton, Executive Vice President of Business Transformation at Unilever and the protagonist of a new Harvard Business School case study supported by Emilie Billaud and Mette Fuglsang Hjortshøj of the Europe Research Center. Unilever was several years into a company-wide plan to revamp its workforce when the coronavirus flared into a pandemic. The multinational entered the crisis braced for change. Dalton discusses how that flexibility has helped Unilever maintain business continuity, provide for worker safety, and coordinate remote work.
  • March 2020
  • Harvard Business Review

HBR Article: Lessons from Italy’s Response to Coronavirus

In this Harvard Business Review article, Professor Gary Pisano and Professor Raffaella Sadun, in collaboration with Michele Zanini from the Management Lab, discuss some of the key takeaways from Italy’s experience, looking particularly at how authorities in Lombardy and Veneto, two neighboring Italian regions, handled the outbreak and saw vastly different results.

New Research on the Region

  • Article
  • npj Digital Medicine

Germany's Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries

By: Sara Gerke, Ariel D. Stern and Timo Minssen

Reimbursement is a key challenge for many new digital health solutions, whose importance and value have been highlighted and expanded by the current COVID-19 pandemic. Germany’s new Digital Healthcare Act (Digitale–Versorgung–Gesetz or DVG) entitles all individuals covered by statutory health insurance to reimbursement for certain digital health applications (i.e., insurers will pay for their use). Since Germany, like the United States (U.S.), is a multi-payer health care system, the new Act provides a particularly interesting case study for U.S. policymakers. We first provide an overview of the new German DVG and outline the landscape for reimbursement of digital health solutions in the U.S, including recent changes to policies governing telehealth during the COVID-19 pandemic. We then discuss challenges and unanswered questions raised by the DVG, ranging from the limited scope of the Act to privacy issues. Lastly, we highlight early lessons and opportunities for other countries.

  • July 2020
  • Article
  • Health Affairs

Lessons From The Impact of Price Regulation on The Pricing Of Anticancer Drugs in Germany

By: Victoria D. Lauenroth, Aaron S. Kesselheim, Ameet Sarpatwari and Ariel Dora Stern

Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the U.S., it remains largely unaddressed there. In Europe, however, different approaches to regulating drug prices have been implemented. Under the 2011 German Pharmaceutical Market Restructuring Act (Arzneimittelmarktneuordnungsgesetz, or AMNOG), for example, manufacturers freely set the prices of newly authorized drugs during their first year on the market. Benefit assessments are carried out during this year and then used in price negotiations between manufacturers and representatives of the country’s statutory health insurers. Using data on 57 anticancer drugs launched in Germany from 2002 to 2017, we found that implementation of AMNOG was associated with drug prices being more closely aligned with clinical benefit. Introducing price negotiations led to a 24.5% decrease in negotiated prices relative to launch prices. We did not find evidence that manufacturers responded by setting higher launch prices. AMNOG is an example of how government price negotiation can be designed to better align prices with clinical benefit without delaying patient access.

  • June 2020
  • Case

What IKEA Do We Want?

By: Cynthia A. Montgomery, Juan Alcacer, Emilie Billaud and Vincent Marie Dessain

In 2018, Swedish furniture maker IKEA was undergoing a significant transformation. Challenged by the rise of online shopping and changing consumer behavior, and mourning the death of its founder, the Company's top executives knew they had to step out of their comfort zones and embrace new strategic initiatives to stay relevant. But which initiatives, executed where, when and how, would enable IKEA to achieve its goals in a way that was profitable while creating an IKEA they would want to pass on to the next generation of co-workers and customers?

See more research

Paris Staff

Vincent Dessain
Executive Director
Daniela Beyersdorfer
Senior Associate Director, Research and Administration
Emilie Billaud
Assistant Director
Giulia Bussoletti
Executive Assistant
Elena Corsi
Assistant Director
Federica Gabrieli
Research Associate
Mette Hjortshoej
Research Associate
Tonia Labruyere
Research Associate
Emer Moloney
Senior Researcher
Jan Pianca
Associate Director, Educational Programs
Oksana Sichi
Assistant Director, Administration